Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate

Wang, 1979, Purification of a human prostate specific antigen, Invest Urol, 17, 159 Oesterling, 1991, Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostrate, J Urol, 145, 907, 10.1016/S0022-5347(17)38491-4 Lilja, 1985, A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein, J Clin Invest, 76, 1899, 10.1172/JCI112185 Stenman, 1991, A complex between prostate specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer, Cancer Res, 51, 222 Lilja, 1991, Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin, Clin Chem, 37, 1618, 10.1093/clinchem/37.9.1618 Christensson, 1993, Serum prostate specific antigen complexed to al-antichymotrypsin as an indicator of prostate cancer, J Urol, 150, 100, 10.1016/S0022-5347(17)35408-3 Lilja, 1994, Improved separation between normals, benign hyperplasia (BPH) and carcinoma of the prostate (CaP) by measuring free (F), complexed (c) and total concentrations (T) of prostate specific antigen (abstract no. 692), J Urol, 151, 400A Catalona, 1995, Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening, JAMA, 274, 1214, 10.1001/jama.274.15.1214 Luderer, 1995, Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen, Urology, 46, 187, 10.1016/S0090-4295(99)80192-7 Catalona, 1982, Staging errors in clinically localized prostatic cancer, J Urol, 127, 452, 10.1016/S0022-5347(17)53862-8 Zincke, 1994, Long-term (15 years) results after radical prostatectomy for clinically localized disease (stage T2c or lower) prostate cancer, J Urol, 152, 1850, 10.1016/S0022-5347(17)32399-6 Zincke, 1991, Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome, J Urol, 146, 1053, 10.1016/S0022-5347(17)37999-5 Gleason, 1977, Histologic grading and staging of prostatic carcinoma, 171 Montie, 1992, staging system for prostate cancer, Semin Urol, 11, 10 Winkler, 1988, Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry, Mayo Clin Proc, 63, 103, 10.1016/S0025-6196(12)64942-8 Paulson, 1990, Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results, J Urol, 144, 1180, 10.1016/S0022-5347(17)39686-6 Cheng, 1993, Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome, Urology, 42, 283, 10.1016/0090-4295(93)90617-J Hudson, 1989, Clinical use of prostate specific antigen in patients with prostate cancer, J Urol, 142, 1011, 10.1016/S0022-5347(17)38972-3 Lange, 1989, The value of serum prostate specific antigen determinations before and after radical prostatectomy, J Urol, 141, 873, 10.1016/S0022-5347(17)41037-8 Partin, 1990, Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia, J Urol, 143, 747, 10.1016/S0022-5347(17)40079-6 Kleer, 1993, Ability of preoperative serum prostate-specific antigen values to predict pathologic stage and DNA ploidy, Urology, 41, 207, 10.1016/0090-4295(93)90558-R Stamey, 1989, Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. Untreated patients, J Urol, 141, 1070, 10.1016/S0022-5347(17)41174-8 Bjork, 1994, Alpha1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia, Urology, 43, 427, 10.1016/0090-4295(94)90225-9 Blute, 1989, Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy, J Urol, 142, 1262, 10.1016/S0022-5347(17)39051-1 Carmichael, 1995, Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease, J Urol, 153, 1015, 10.1016/S0022-5347(01)67625-0 Lerner, 1996, Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy, J Urol, 156, 137, 10.1016/S0022-5347(01)65967-6 Nativ, 1990, Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma, J Urol, 144, 303, 10.1016/S0022-5347(17)39437-5 Mitrunen, 1995, Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum, Clin Chem, 41, 1115, 10.1093/clinchem/41.8.1115 Bluestein, 1994, Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer, J Urol, 151, 1315, 10.1016/S0022-5347(17)35239-4 Blackwell, 1994, Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen density, J Urol, 151, 1565, 10.1016/S0022-5347(17)35303-X